Last reviewed · How we verify
r-PA
At a glance
| Generic name | r-PA |
|---|---|
| Also known as | Recombinant Human Tissue Plasminogen Kinase Derivative for Injection |
| Sponsor | Angde Biotech Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Alteplase Through an Indwelling Pleural Catheter for the Management of Symptomatic Septated Malignant Pleural Effusion (EARLY_PHASE1)
- Clinical Treatments in Specialized Diseases of Laryngeal Carcinoma (LC) and Hypopharyngeal Carcinoma (HPC)
- A PAN-USR TB Multi-Center Trial (PHASE3)
- Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB (PHASE2)
- Accuracy of the Association Between the "PA-R" and "ACT" Questionnaires in Asthmatic Pediatric Patients (NA)
- A Study of r-PA Treating Patients With Acute Ischemic Stroke（RAISE） (PHASE3)
- Non-invasive Diagnosis of Invasive Pulmonary Aspergillosis by Use of Biomarkers in Exhaled Breath Condensate
- Targeting TFPI With Concizumab to Improve Haemostasis in Glanzmann Thrombasthenia Patients: an in Vitro Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |